Answers are grounded in this paper and cite their sources.
This commentary emphasizes the need for caution, rigorous patient selection, and meticulous monitoring when introducing warfarin for atrial fibrillation in primary care, noting the high exclusion rates and frequent under-anticoagulation observed in clinical trials.
fibrillation in Britain, on the prevalence of indications and contraindications for anticoagulation, on factors that influence doctors' decisions to offer treatment and patients' decisions to accept it, and on the costs and benefits of anticoagulant treatment in primary and secondary care.Funding: CMS is funded by the Medical Research Council.Conflict of interest: The authors are involved in a study of the prevalence of atrial fibrillation and of indications and contraindications for treatment with warfarin, which is funded by the Stroke Association. 1
No takes yet. Share an insight, caveat, or question.
Sweeney et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: